Amount of gene surplus determines severity of mental retardation in males
It is for first time that scientists have linked the degree of a mental illness to the number of copies of a gene on the X-chromosome, normally present as a single copy in males. The mental handicap is much more severe in patients with 5 copies than in patients with 2 copies. An intermediate severity has been observed in case of 3 copies. In their publication, the scientists also present a new mechanism by which such defects can arise. This mechanism might also underlie other genetic disorders.
Defects in the GDI1 gene have previously been found in a few XLMR (X-Linked Mental Retardation) patients. In these patients, the production of GDI1 in the brain is disturbed, which impedes the transfer of stimuli in the brain. The new finding in this research is that over-production of GDI1 is also harmful. The higher the production, the greater the disruption of signals.
The discovery was made through DNA research in several families in which only males are afflicted with a mental handicap. In such families, defects appear on the X-chromosome (thus the name X-Linked Mental Retardation). Males have only one version of the X-chromosome. Females have a reserve copy, through which defective information can be masked.
Mental handicap occurs in 2 - 3% of the population. The handicap can be attributed to external factors, such as a deficiency in oxygen at birth, or to defects in the DNA. When the cause is genetic (hereditary), exact identification of the defect is crucially important for providing the patient with the proper medical support or for assessing the risk involved for couples with child wish. Recent estimates are that a defect on the X-chromosome is the cause in about 12% of the patients. However, in over half of the XLMR patients, the responsible gene has not yet been identified. This research makes a contribution toward filling this gap in our knowledge.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.